1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
GeneOne Life Science, Inc.

GeneOne Life Science, Inc.

011000.KS
GeneOne Life Science, Inc.KR flagKorea Exchange
1,084.00
KRW
+11.00
- -
19.66BMarket Cap

Total Valuation

GeneOne Life Science, Inc. carries a market capitalization of 19.66B, placing it among publicly traded companies globally. Its enterprise value stands at 418.87B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap19.66B
Enterprise Value418.87B

Share Statistics

GeneOne Life Science, Inc. currently has 90.67M shares outstanding.

Shares Outstanding90.67M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 22.80, and the price-to-book ratio stands at -1.71.

PE RatioN/A
PS Ratio22.80
PB Ratio-1.71
P/TBV Ratio7.67
P/FCF Ratio-24.54
P/OCF Ratio-24.56

Enterprise Valuation

EV / Sales24.46
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

GeneOne Life Science, Inc. maintains a current ratio of 0.46, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 66.76, indicating elevated leverage, while an interest coverage ratio of -8.94 demonstrates limited ability to service its debt obligations.

Current Ratio0.46
Quick Ratio0.11
Debt / Equity66.76
Debt / EBITDA-0.81
Interest Coverage-8.94

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-32.95
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.05

Taxes

Income Tax-109.21M
Effective Tax RateN/A

Stock Price Statistics

GeneOne Life Science, Inc.'s stock has declined approximately -92.80929% over the past 52 weeks. The 50-day moving average sits at 1,010.72, while the 200-day moving average is 1,709.59.

Beta (5Y)N/A
52-Week Price Change-92.80929%
50-Day Moving Average1,010.72
200-Day Moving Average1,709.59
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, GeneOne Life Science, Inc. generated 17.12B in revenue and converted that into -45.40B in net income, yielding earnings per share of -532.51. EBITDA reached -42.05B, while operating income came in at -42.05B.

Revenue17.12B
Gross Profit-13.33B
Operating Income-42.05B
Pretax Income-45.50B
Net Income-45.40B
EBITDA-42.05B
EBIT-42.05B
Earnings Per Share (EPS)-532.51

Balance Sheet

GeneOne Life Science, Inc. holds 5.72B in cash and equivalents against 34.15B in total debt, resulting in a net debt position of 25.21B. Total book value stands at -228.34B, with working capital of -29.25B providing operational flexibility.

Cash & Cash Equivalents5.72B
Total Debt34.15B
Net Debt25.21B
Equity (Book Value)-228.34B
Book Value Per Share-2,678.47
Working Capital-29.25B

Cash Flow

GeneOne Life Science, Inc. produced -15.90B in operating cash flow over the past twelve months. After subtracting 15.27M in capital expenditures, free cash flow totaled -15.88B - equivalent to -186.30 per share.

Operating Cash Flow-15.90B
Capital Expenditures15.27M
Free Cash Flow-15.88B
FCF Per Share-186.30

Margins

GeneOne Life Science, Inc. operates with a gross margin of -77.83, reflecting its pricing power and cost economics. The operating margin of -245.59 and net profit margin of -265.13 provide insight into operational efficiency.

Gross Margin-77.83
Operating Margin-245.59
Pretax Margin-265.77
Profit Margin-265.13
EBITDA Margin-245.59

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-5.63
FCF Yield-4.08

Stock Splits

GeneOne Life Science, Inc.'s most recent stock split took place on May 14, 2026 with a 5:1 split ratio.

Last Split Date5/14/2026
Split Ratio5:1

Scores

GeneOne Life Science, Inc. posts an Altman Z-Score of -1.68, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-1.68